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General Information
We all have heard about the use of BST in lactating dairy cattle during the last 6
to 8 years, but what is BST? Bovine somatotropin is another dairy management tool
developed to improve the efficiency and reduce the cost of producing milk. It is the newest
in a list of technological advances in the dairy industry, such as genetic improvements,
nutrition, health, housing, milking equipment and techniques, embryo transfer, and DHI
records.
BST is a natural protein produced in the anterior pituitary gland of all cattle. Like
other proteins, BST is composed of various amino acids (190-199). BST is bovine growth
hormone, somatotropin. It helps to allocate energy from feed to meet the physical needs
of the cows, such as growth in young animals, milk production in mature animals, and other
functions in the body.
What does BST do? Supplemental BST stimulates cows to produce more milk from
a proportionately smaller increase in feed consumption. Therefore. less feed is required to
produce a pound of milk (Figure 1).
Peak milk production is
normally reached in the second to
third mo (50 to 65 days) of the 10-
month lactation period, then it
decreases until lactation finally
ceases. Supplemental BST extends
the duration of near-peak milk
production consistent with the
genetic and environmental potential
of the cow (Figure 2).
How does  BST  work?
Scientific research shows that BST is
produced in the anterior pituitary,
released to the bloodstream, and
activates “BST receptors” for specific Figure 1. Feed efficiency improvement.
needs of the body. For example,
“Growth receptors” in young animals
direct food energy into normal growth; when the animal matures, the growth receptors shut
down. In mature animals, “Mammary receptors” are activated as cows complete pregnancy.
These receptors help direct energy in the feed into milk production.
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It is known that cows
receiving supplemental BST
consume more feed. Additional
feed consumption and milk
production are related to the
amount of BST administered.
Therefore, BST stimulates the cow
to produce more milk, which results
in increased intake to provide the
extra energy required. More of that
energy is directed into milk
production rather than body
maintenance.
How is BST made? BST
can be produced in commercial
quantity using recombinant DNA
technology. The gene responsible
for natural BST production in dairy
cows has been isolated and can be
transferred to ordinary bacterial
cells. The bacteria are then used to
produce large quantities of BST
through fermentation techniques.
After this process, the bacteria are
killed, and BST is separated, highly
purified, and formulated for use in
cattle (Figure 3).
How safe is BST? Before a
new animal drug such as BST may
be marketed commercially, it must
be found to be safe and effective in
the target animal, safe from the
s tandpoin t  of human food
consumption, and safe for the
environment. FDA’s Center for
Figure 2. BST effectiveness.
Figure 3. Production of BST.
Veterinary Medicine (CVM) is responsible for assuring that these standards are met prior
to commercial marketing. With BST, the sponsors were able to demonstrate very early in
the process that there were no changes in residues of BST in the milk from lactating dairy
cows treated with BST and that even if there were, such residues would represent no risk
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Table 1.  Milk Composition
        Supplemental BST (mg/day)
Measurement 0 12.5 25 50
Milk fat, % 3.65 4.00 3.65 4.00
Milk protein, % 3.00 3.04 3.03 2.98
Total solids, % 12.31 12.99 12.55 12.78
University of Pennsylvania
38 wk beginning at wk 4 to 5 of lactation
no changes in residues of BST in the milk from lactating dairy cows treated with BST and that even
if there were, such residues would represent no risk 
to humans consuming the milk.  This finding by the FDA's Division of Human Food and
Environmental Safety is based on four facts about BST:
a. BST is a protein that, when ingested, is broken down or digested in the human
gastrointestinal tract and thus inactivated.  (BST is inactive even in cows when given
orally.)
b. BST is species specific.  That is, even if BST is injected into humans, it is still i active.
The somatotropins from some species are fairly similar and may cross-react.  However,
that is not the case with respect to BST in humans.  A number of years ago, BST was
investigated as a drug for treatment of growth disorders in child en and was found to be
INACTIVE in humans even when injected.
c. No difference has been detected in the milk from cows receiving supplemental BST and
the milk from other cows or from the same cows before they received supplemental BST.
Milk from cows treated with BST cannot be distinguished from milk from nontreated
cows.  Trace amounts of BST occur naturally in cows' milk at variable levels, generally
less than two parts per billion but occasionally ranging up to 10 parts per billion.  No
increase in BST levels in milk has been obs rved in cows receiving supplemental BST at
expected use levels.
d. Humans consuming animal derived food products always have been exposed to small
amounts of naturally produced BST in milk and meat.
The composition of
milk (with respect to lactose,
protein, and fat) obtained
from BST-supplemented
cows is not different than
that of milk from cows that
are not supplemented
(Table 1).
Milk and meat from
cows in a limited number of
continuing BST trials con-
ducted under Investigational
New Animal Drug proce-
dures have been authorized
by FDA for sale and commercial use.  Registration and commercial availability of BST are expected
about 1990.
How safe is BST for the animals?  BST used at anticipated commercial dosages has shown no
undesirable effects on cows receiving it or on their calves.  Long-term trials are continuing to confirm
that supplemental BST used through multiple lactations is safe for cows.  Res archers hav  found that
cows receiving supplemental BST at the tested dosages showed no significant difference in:
ll
l
l
l
l
incidence of mastitis, milk fever, or ketosis;
conception rates and services per conception;
birth weights of calves and calf growth rates after birth;
normal late-lactation weight gain;
temperament or behavior of treated cows; or
production of cows during the following lactation when they
Studies at more than 20 universities, over 15 private herds,
confirm many of these observations.
How will cows perform with respect
to milk production and feed efficiency?
Supplemental BST is expected to lower the
cost of milk production by increasing the
milk produced per pound of feed consumed.
Cows receiving supplemental BST produce
an average of about 12% (range 10 to
25%) more milk. Increased milk response
begins within 24 hr after BST administration
and continues as long as BST is
administered (Figure 4).
Results in different trials show that
supplemental BST, with diets properly ad-
justed to provide the required nutrients, can
improve feed efficiency or the amount of
milk produced per pound of feed consumed
by about 5 to 15% (Figure 5).
did not receive BST.
and other countries
University of Kentucky
38 weeks beginning at week 4 to 5 of lactation
Figure 4. Milk production.
Feed consumption increases with the amount of additional milk produced, but it does
not increase proportionately. Cows receiving supplemental BST must be fed according to
their higher milk production level. Voluntary feed intake may increase sufficiently to
support the increased milk production, allowing use of the same diet in greater quantities,
but voluntary feed intake may be limited by stomach capacity, requiring ration reformulation
at higher nutrient densities.
What are the economic effects and industry impact of BST? The economic effects
of BST have been researched and are highly predictable. Cows on BST produce from 10
to 25% more milk and consume about 5 to 15% more feed to produce the additional milk.
Thus, cows require about 5 to 10% less feed to produce a lb of milk, resulting in lower
costs and a higher return for dairymen. BST will require little if any capital investment,
unlike many dairy industry advances. It will be equally accessible to small herds and to
larger, well capitalized operations. The cost of BST has not yet been established, but BST
must be priced to yield a desirable profit to dairymen or they will not use it. The speed
with which BST takes effect will offer dairymen an increased range of options to manage
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milk production and farm income. BST will
provide the ability to increase herd average
by producing the same amount of milk from
fewer cows or more milk from the same
cows; adjust milk production up or down to
meet changing market or farm conditions
within days; raise or maintain desired farm
income without the need for more cows or
farm facilities; and adjust farm operations to
realize the same production/income with a
reduced workload. Adoption of BST is
expected to be gradual. It is unlikely that
the maximum adoption rate will exceed 50
to 60% and even people that use it will not
use BST immediately on their entire herds. Universi ty of Minnesota
38 weeks beginning at week 4 to 5 of lactation
Conclusions
Figure 5. Feed efficiency.
There is an important interaction
between the dose of somatotropin, the time of the initiation of treatment, and the nutrition
and management of the herd. The BST-treated cow is like the high-producing cow, and
similarly, poor nutrition can restrict and superior nutrition can augment responses. BST can
improve feed efficiency and milk performance, but it does not work alone. Improved
performance and increased efficiency will be realized only when the level of management,
nutrition, and herd health are concomitant with the management of our good and better-
producing herds today. To be competitive in world and domestic markets, agricultural
enterprises in the U.S. must strive for economic efficiency. Advances in nutrition,
management, and sire-proofing programs have resulted in impressive increases in productivity
and efficiency, and BST is the first product of biotechnology with potential to have a major
impact upon productivity.
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